BioPontis Board Members are committed to innovation

FOR RELEASE: 2017 1 November

BioPontis Board Members are committed to innovation

Brussels, Belgium and Raleigh, NC USA

The European Union has made a multi-year, 7-billion dollar investment in research and innovation towards improving its citizens’ health. Listen as BioPontis Alliance Board member Dr. Jean-Jacques Cassiman discusses his role in EuroGentest, a project funded by the EU, to advance genetic testing across Europe. (Personalising healthcare: Focusing on citizens’ health – European Commission, 2017, 1:53)


About BioPontis Alliance for Rare Diseases

BioPontis Alliance for Rare Diseases is a 501c(3) public charity in the US (North Carolina) and a foundation of public utility (fup/son) in Belgium (Brussels). Managed by an international Board and executive team, BioPontis partners with patient organizations and clinical researchers to bridge the gap between promising science and new medicines. BioPontis Alliance for Rare Diseases is being established as a global non-profit, inviting corporate, private and foundation philanthropic support. More information, including how contributions to support our programs and mission can be made, at http://biopontisalliance.org.

 

Contacts:

Erik Tambuyzer, Chairperson BioPontis Alliance for Rare Diseases
+32 475 61 57 11 (Brussels, Belgium)
Erik.Tambuyzer@biopontisalliance.org

Richard Basile, CEO BioPontis Alliance for Rare Diseases
+1 919 345 5386 (Raleigh, USA)
Richard.Basile@biopontisalliance.org